These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36503167)

  • 1. Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study.
    Rice BA; Naimi TS; Long MT
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2854-2863.e2. PubMed ID: 36503167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis.
    Ajmera V; Belt P; Wilson LA; Gill RM; Loomba R; Kleiner DE; Neuschwander-Tetri BA; Terrault N;
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1511-1520.e5. PubMed ID: 29378307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
    Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
    J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease.
    Long MT; Massaro JM; Hoffmann U; Benjamin EJ; Naimi TS
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1831-1841.e5. PubMed ID: 31734449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
    Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
    Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroscan-Aspartate Aminotransferase Score Predicts Liver-Related Outcomes, but Not Extrahepatic Events, in a Multicenter Cohort of People With Human Immunodeficiency Virus.
    Sebastiani G; Milic J; Kablawi D; Gioè C; Al Hinai AS; Lebouché B; Tsochatzis E; Finkel J; Ballesteros LR; Ramanakumar AV; Bhagani S; Benmassaoud A; Mazzola G; Cascio A; Guaraldi G
    Clin Infect Dis; 2023 Aug; 77(3):396-404. PubMed ID: 37013396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study.
    Chang Y; Cho YK; Kim Y; Sung E; Ahn J; Jung HS; Yun KE; Shin H; Ryu S
    Hepatology; 2019 Jan; 69(1):64-75. PubMed ID: 30019340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study.
    Kelly EM; Dodge JL; Bacchetti P; Sarkar M; French AL; Tien PC; Glesby MJ; Golub ET; Augenbraun M; Plankey M; Peters MG
    Clin Infect Dis; 2017 Nov; 65(12):2050-2056. PubMed ID: 29020382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Kechagias S; Önnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall HU; Hultcrantz R; Stål P
    Scand J Gastroenterol; 2017 Feb; 52(2):159-165. PubMed ID: 27650916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease.
    Ting PS; Lin WT; Huang CK; Lin HY; Tseng TS; Chen PH
    Alcohol Clin Exp Res (Hoboken); 2024 Jan; 48(1):88-97. PubMed ID: 38206286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.
    Mitchell T; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Ching H; Hamdorf J; Adams LA
    Am J Gastroenterol; 2018 Oct; 113(10):1484-1493. PubMed ID: 29899440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
    Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
    Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
    Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort.
    Llop E; Iruzubieta P; Perelló C; Fernández Carrillo C; Cabezas J; Escudero MD; González M; Hernández Conde M; Puchades L; Arias-Loste MT; Serra MÁ; Crespo J; Calleja JL
    United European Gastroenterol J; 2021 Oct; 9(8):892-902. PubMed ID: 34077628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology.
    Calleja JL; Rivera-Esteban J; Aller R; Hernández-Conde M; Abad J; Pericàs JM; Benito HG; Serra MA; Escudero A; Ampuero J; Lucena A; Sánchez Y; Arias-Loste MT; Iruzubieta P; Romero-Gómez M; Augustin S; Crespo J
    Liver Int; 2022 Aug; 42(8):1783-1792. PubMed ID: 35643936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease.
    Kashiwagi K; Yamaguchi A; Shiba S; Taniki N; Inoue N; Takaishi H; Iwao Y; Kanai T
    Alcohol; 2020 Dec; 89():1-7. PubMed ID: 32738385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).
    Dunn W; Sanyal AJ; Brunt EM; Unalp-Arida A; Donohue M; McCullough AJ; Schwimmer JB
    J Hepatol; 2012 Aug; 57(2):384-91. PubMed ID: 22521357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.
    Younossi ZM; Stepanova M; Ong J; Yilmaz Y; Duseja A; Eguchi Y; El Kassas M; Castellanos-Fernandez M; George J; Jacobson IM; Bugianesi E; Wong VW; Arrese M; de Ledinghen V; Romero-Gomez M; Mendez-Sanchez N; Ahmed A; Wong R; Papatheodoridis G; Serfaty L; Younossi I; Nader F; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1625-1633.e1. PubMed ID: 30476585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.